ALRN
Price:
$2.11
Market Cap:
$25.60M
Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting peripheral T-cell lymphoma, and a Phase I trial for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Furthermore, ALRN-6924 is involved in combination studies: a Phase 1b trial testing its efficacy with cytarabine (Ara-C) in patients with MDS, and a Phase 2a combination trial with palbociclib for individuals with tumors exhibiting MDM2...[Read more]
Industry
Biotechnology
IPO Date
2017-06-29
Stock Exchange
NASDAQ
Ticker
ALRN
According to Aileron Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -258.45%. This represents a change of 116.19% compared to the average of -119.55% of the last 4 quarters.
The mean historical ROE of Aileron Therapeutics, Inc. over the last ten years is -41.10%. The current -258.45% ROE has changed 528.83% with respect to the historical average. Over the past ten years (40 quarters), ALRN's ROE was at its highest in in the June 2016 quarter at 0%. The ROE was at its lowest in in the June 2025 quarter at -226.80%.
Average
-41.10%
Median
-0.10%
Minimum
-294.78%
Maximum
0%
Discovering the peaks and valleys of Aileron Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 0%
Minimum Annual Increase = 0%
Minimum Annual ROE = -294.78%
| Year | ROE | Change |
|---|---|---|
| 2025 | -294.78% | 154.98% |
| 2024 | -115.61% | 50.51% |
| 2023 | -0.23% | 55.66% |
| 2022 | -0.15% | 146.25% |
| 2021 | -0.06% | -65.74% |
| 2020 | -0.17% | -Infinity% |
| 2019 | 0% | 0% |
| 2018 | 0% | 0% |
| 2017 | 0% | 0% |
| 2016 | 0% | 0% |
The current ROE of Aileron Therapeutics, Inc. (ALRN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-136.87%
5-year avg
-82.17%
10-year avg
-41.10%
Aileron Therapeutics, Inc.’s ROE is less than Lunai Bioworks Inc. (892.52%), greater than Magenta Therapeutics, Inc. (-27.30%), greater than GreenLight Biosciences Holdings (-1847.24%), less than Pluristem Therapeutics Inc. (79.27%), greater than AlloVir, Inc. (-72.78%), greater than Spyre Therapeutics, Inc. (-31.25%), less than bluebird bio, Inc. (129.26%), greater than Kronos Bio, Inc. (-40.83%), greater than ERYTECH Pharma S.A. (-95.68%), greater than Lumos Pharma, Inc. (-78.34%),
| Company | ROE | Market cap |
|---|---|---|
| 892.52% | $32.92M | |
| -27.30% | $42.44M | |
| -1847.24% | $45.43M | |
| 79.27% | $40.85M | |
| -72.78% | $49.48M | |
| -31.25% | $5.34B | |
| 129.26% | $48.67M | |
| -40.83% | $53.65M | |
| -95.68% | $47.38M | |
| -78.34% | $37.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aileron Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aileron Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aileron Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aileron Therapeutics, Inc. (ALRN)?
What is the highest ROE for Aileron Therapeutics, Inc. (ALRN)?
What is the 3-year average ROE for Aileron Therapeutics, Inc. (ALRN)?
What is the 5-year average ROE for Aileron Therapeutics, Inc. (ALRN)?
How does the current ROE for Aileron Therapeutics, Inc. (ALRN) compare to its historical average?